AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04880135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised stretching and strengthening exercise
Description: The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
Study NCT04880135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based stretching and strengthening exercise
Description: The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
Study NCT04664179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 1A: 2 x 10^7 cells/m2
Description: 2 x 10\^7 cells/m2
Study NCT04664179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2A: 6 x 10^7 cells/m2
Description: 6 x 10\^7 cells/m2
Study NCT04664179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2B: 6 x 10^7 cells/m2
Description: 6 x 10\^7 cells/m2
Study NCT04664179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 3B: 2 x 10^8 cells/m2
Description: 2 x 10\^8 cells/m2
Study NCT04664179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 3A: 2 x 10^8 cells/m2
Description: 2 x 10\^8 cells/m2
Study NCT05058547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWEPPE
Description: In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
Study NCT05443633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized speech-language training
Description: Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
Study NCT05443633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard language intervention
Description: Participants will undergo standard speech-language naming therapy
Study NCT06176222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRECEDEX INJ★ 2ML
Description: patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
Study NCT06176222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
Study NCT05619263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disaster PrepWise-Caregiver
Description: The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
Study NCT05568212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
Study NCT05568212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet
Description: Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
Study NCT05568212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Description: Investigator's choice single-agent chemotherapy regimen
Study NCT05568212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent chemotherapy
Description: Investigator's choice single-agent chemotherapy regimen
Study NCT06479499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: Group A will undergo Pilates exercise training, scheduled three times weekly over an 8-week period, for elderly individuals with COPD the duration and time interval time for Pilates exercise can vary depending on their overall health, fitness level, and tolerance. It begins with warm-up with 10-15 minutes which may include gentle stretches and deep breathing Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The exercise sessions lasting around 10-15 minutes and then gradually progressing to 20-30 minutes as the participants become more comfortable and their endurance improves. Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The rest interval will be 1-2 minutes between exercise and then gradually reducing it to 30 seconds or less. Pilates session ends with a cool-down which may involve stretching and relaxation with duration of about 5-10 minutes.
Study NCT06479499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Group B will engage in Aerobic exercise plan, following the same frequency and duration as the Pilates exercise program-three sessions per week for 8 weeks, It begins with a warm-up of 5-10 minutes to prepare body for exercise it includes gentle movements, stretching, or a few minutes of low-intensity aerobic activity. It includes main exercise with moderate intensity like brisk walking or jogging with duration of 5-10 minutes and increase to 20-30 minutes as participants improves their endurance. The short interval begins with 1-2 minutes than gradually reducing it to 30 seconds or less as a person builds up stamina and fitness. The cool-down duration at end of exercise will be 5-10 minutes.
Study NCT04734067 — intervention group
Intervention type: OTHER
Intervention: Immune checkpoint inhibitors(ICIs) therapy
Description: Patients with malignant tumors who first received ICIs
Study NCT05844267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental led booster breaks
Description: Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.
Study NCT05844267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental unled computer-prompts
Description: Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary.
Study NCT06056661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WMR
Description: Participants will complete up to five sessions that will take 2 hours each. Sessions will take place in person. Participants will learn skills related to getting into and out of romantic relationships and identifying and pursuing goals for romantic relationships.
Study NCT06341556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
Study NCT05982496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FES
Description: 16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
Study NCT05982496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI A
Description: An additional FES PET/MRI will be performed before surgery.
Study NCT05982496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI B
Description: Two additional PET/MRI will be performed before and after induction ET.
Study NCT05982496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI C
Description: Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.
Study NCT05982496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI D
Description: Two additional PET/MRI will be performed before and after two cycles of systemic therapy.
Study NCT05982496 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Translational analysis
Description: Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
Study NCT04990037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04
Description: Administered intravenously
Study NCT04990037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Administered intravenously
Study NCT06531837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine(Continuous infusion)
Description: Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.
Study NCT06531837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil (Target-Controlled Infusion)
Description: The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.
Study NCT06531837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (Single intravenous injection)
Description: Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.
Study NCT06531837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.
Study NCT06531837 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: Collect resting-state EEG data and NRS scores.
Study NCT05966584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab 30mg subcutaneously on day -1.
Study NCT05966584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant or AIs) and PI3K inhibition (alpelisib)
Description: SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
Study NCT06490497 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: individual interviews semi-directive
Study NCT06301074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10509
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.
Study NCT06587360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fertiShare intervention - sharing bad news eLearning course
Description: two-hour self-led eLearning course to support fertility staff in sharing bad news (SBN) with their patients~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 offers SPIKES-based step-by-step guidance to ease SBNs. Module 3 offers guidance to cope with common challenges FHPs face: sharing bad news remotely, managing anger and uncertainty, and using good news to lessen the impact of bad news.~Each module offers video content-based lessons, case studies that illustrate guidance and brief quizzes for self-reflection and assessment. Case studies show learners optimal and suboptimal approaches to SBN.
Study NCT06587360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fertiShare control - basic communication skills eLearning course
Description: self-led eLearning course branded as fertiShare but designed to emulate the basic communication training healthcare providers receive as they undergo their professional degrees.~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 introduces the communication cycle and associated communication techniques. Module 3 offers guidance regarding other basic communication skills: empathic communication, non-verbal communication, active listening and remote consultations, and communicating the likelihood of positive or negative treatment outcomes.~Each module offers video content-based lessons, case studies, and brief quizzes. All teaching elements remain at the basic level (remembering and understanding instead of analysing and applying).
Study NCT05586165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder to boost protection against COVID-19
Description: Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.
Study NCT05586165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu Tag Along
Description: This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).
Study NCT05586165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Booster & Flu Bundle
Description: This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
Study NCT06698276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Reconstruction
Description: It will be used a combination of two biomaterials for alveolar ridge preservation
Study NCT06301074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.
Study NCT06700395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2029 injection
Description: TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.
Study NCT04527510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional-reading
Description: Two radiologists interpret at least three views of each breast without AI independently.
Study NCT04527510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Second-reading
Description: One radiologist reads AB US images without AI first, then combines the indications of AI marks to make the final decision.
Study NCT04527510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Concurrent-reading
Description: One radiologist identifies CAD marks first, then quickly browses the entire AB US examination to make the final decision.
Study NCT04527510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tow views-reading
Description: Two radiologists interpret only two views of each breast without AI independently.
Study NCT04527510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Handheld US-screening
Description: One radiologist screens the breast cancer using Handheld US and interprets images immediately.
Study NCT06721819 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention
Description: Preoperative Sleep Hygiene and Brain game followed by post operative IV acetaminophen administration
Study NCT06721819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Three doses of IV acetaminophen (as following ERAS protocol) at 1000mg per dose within 48 hours post operatively.
Study NCT06720116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sustained natural apophysial glide
Description: The patients will be in the sitting position and asked to move their head in the direction that particularly produces their symptoms. As the participant moves their head, the physiotherapist gently glides the painful vertebra anteriorly and sustains the glide through the movement.~During the application of the glide, the participant should stay symptom free and is instructed to stop moving if any PAIN is produced. This movement was repeated for 10 times for 3 sets, The interval between the sets was 15 to 20 seconds.After mobilization subject had to perform same exercises as conventional group plus conventional physical therapy
Study NCT06720116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument assisted soft tissue mobilization
Description: The subject will be in comfortable sitting position leaning on a treatment table with the arm crossed to rest the head. After cleaning the skin of the subject and the blade with alcohol swabs, a lubricant (Vaseline) was applied, and a sweeping technique was used to apply a deep yet comfortable soft tissue mobilization on the upper trapezius from origin to insertion for approximately 3 min.~First, M2T blade will be utilized to locate the precise locations of limitation in the affected muscles. Second, the M2T blade was put at 45 degree angle by using convex surface to apply gentle strokes along the muscle. Subjects were instructed that slight hyperemia on the skin is a normal feeling and should subside before the next session.
Study NCT06720116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises
Study NCT06720116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises
Study NCT06721377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Novaloc attachment
Description: upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region \& will be loaded by Novaloc attachment.
Study NCT06721377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Equator attachment
Description: upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region\& will be loaded by Equator attachment.